研发费用和一般行政费用 - 研发费用增加约83.7万美元至192.5万美元，主要由于乳腺癌疫苗和CAR-T治疗项目的外部研发费用增加[88] - 一般及行政费用减少约8.9万美元至166.7万美元，主要由于董事股票期权补偿费用和董事费用减少[89] 收入和利息收入 - 公司未产生任何收入，预计短期内不会从治疗和疫苗项目获得收入[85][86][93][95] - 利息收入减少约1.9万美元至27.7万美元，主要由于短期投资平均金额减少，但利率上升[91] 现金和融资 - 公司现金、现金等价物和短期投资为2.0745亿美元，较2023年10月31日减少约309.9万美元[103] - 公司通过"随时市场"股票发行筹集约298.4万美元资金，截至2024年7月31日尚可发行约9700万美元股票[103] - 公司认为现有现金、现金等价物和短期投资足以维持至少12个月的运营[103] 会计政策和内部控制 - 公司收入确认、股票期权补偿和研发费用确认涉及重大判断和估计[106][107][108][109][112][113] - 公司使用Black-Scholes定价模型和Monte Carlo模拟来估算公允价值，需要做出预期期限、预期波动率、无风险利率和预期股息收益率等估值假设[114] - 如果未来获得更多信息表明其他模型更合适，公司将重新考虑使用Black-Scholes定价模型和Monte Carlo模拟[115] - 公司根据与研究机构、临床研究机构、临床制造机构等各方签订的合同确认研发费用，根据管理层估计的活动和任务完成情况、预计服务期限和投入程度进行确认[116,117] - 公司根据管理层对每位员工投入时间和精力的估计将部分内部薪酬成本分摊至研发费用[117] - 公司评估了披露控制和程序的有效性，首席执行官和首席财务官认为其有效[119] - 报告期内公司的内部财务报告控制未发生重大变化[120]

SAN JOSE, Calif., July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin, Ireland. The presentation, titled "Phase I Clinical Trial of Autologous T-cells Genetically Engineered with a Chime ...

IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Moffitt Cancer Center (Moffitt), has received approval by the U.S. Food and Drug Administration (FDA) of an individual patient Investigational New Drug ...

SAN JOSE, Calif., July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Vaccine Adjuvants and Formulations.""This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geograp ...

SAN JOSE, Calif., July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has authorized a share repurchase program of up to $5 million of the Company's outstanding common stock. "This share repurchase program reflects our confidence in the future outlook of our business, the soundness of our balance sheet, the strength of our clinical development pi ...

This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the sec ...

未实现营收情况 - 截至2024年4月30日，公司在2024年第一季度和第二季度均未实现任何营收[44][46] 研发支出增加情况 - 研发支出在2024年第一季度和第二季度分别增加了约648,000美元和929,000美元[45][46] 收入来源 - 公司的收入主要来自技术许可和专利技术销售[52] 一次性许可协议收入 - 总体而言，公司的一次性许可协议为公司带来了210,000美元的收入，但公司未来预计不会依赖于专利许可活动作为主要收入来源[44][46] 股权补偿费用计算方式 - 公司的股权补偿费用是基于 Black-Scholes 定价模型和 Monte Carlo 模拟计算的[53] 研发费用实际发生制度 - 公司对研发费用进行实际发生制度，预付的研发费用会随着服务的提供而逐步支出[54]

Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is be ...

– Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical tr ...

Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on po ...